Regenxbio price target raised to $55 from $45 at Barclays

Barclays raised the firm’s price target on Regenxbio to $55 from $45 and keeps an Overweight rating on the shares. The analyst says the company’s new Duchenne muscular dystrophy gene therapy data from the first patient showed high microdystrophin expression despite old age. A single arm pivotal trial could be feasible per FDA feedback, the analyst tells investors in a research note.